Share this post:

Jop de Vrieze describes the results of the Benchmark with a focus on the performance of the separate categories of companies. The articles states the Foundation hopes that the benchmark will encourage companies to remain active—or even rejoin—the market for antibiotics.

“To gauge their commitment, the Foundation asked companies for detailed information about their research and development programs, manufacturing processes, efforts to make drugs available to populations who need them most…”

Read full article